Boston University School of Medicine, Department of Pathology and Laboratory Medicine, Boston, MA, USA.
Respir Res. 2010 Nov 23;11(1):160. doi: 10.1186/1465-9921-11-160.
Antigen desensitization through oral tolerance is becoming an increasingly attractive treatment option for allergic diseases. However, the mechanism(s) by which tolerization is achieved remain poorly defined. In this study we endeavored to induce oral tolerance to cockroach allergen (CRA: a complex mixture of insect components) in order to ameliorate asthma-like, allergic pulmonary inflammation.
We compared the pulmonary inflammation of mice which had received four CRA feedings prior to intratracheal allergen sensitization and challenge to mice fed PBS on the same time course. Respiratory parameters were assessed by whole body unrestrained plethysmography and mechanical ventilation with forced oscillation. Bronchoalveolar lavage fluid (BAL) and lung homogenate (LH) were assessed for cytokines and chemokines by ELISA. BAL inflammatory cells were also collected and examined by light microscopy.
CRA feeding prior to allergen sensitization and challenge led to a significant improvement in respiratory health. Airways hyperreactivity measured indirectly via enhanced pause (Penh) was meaningfully reduced in the CRA-fed mice compared to the PBS fed mice (2.3 ± 0.4 vs 3.9 ± 0.6; p = 0.03). Directly measured airways resistance confirmed this trend when comparing the CRA-fed to the PBS-fed animals (2.97 ± 0.98 vs 4.95 ± 1.41). This effect was not due to reduced traditional inflammatory cell chemotactic factors, Th2 or other cytokines and chemokines. The mechanism of improved respiratory health in the tolerized mice was due to significantly reduced eosinophil numbers in the bronchoalveolar lavage fluid (43300 ± 11445 vs 158786 ± 38908; p = 0.007) and eosinophil specific peroxidase activity in the lung homogenate (0.59 ± 0.13 vs 1.19 ± 0.19; p = 0.017). The decreased eosinophilia was likely the result of increased IL-10 in the lung homogenate of the tolerized mice (6320 ± 354 ng/mL vs 5190 ± 404 ng/mL, p = 0.02).
Our results show that oral tolerization to CRA can improve the respiratory health of experimental mice in a CRA-induced model of asthma-like pulmonary inflammation by reducing pulmonary eosinophilia.
通过口服耐受进行抗原脱敏治疗正在成为一种越来越有吸引力的治疗过敏疾病的选择。然而,耐受作用的确切机制仍不清楚。在这项研究中,我们试图通过口服耐受蟑螂过敏原(CRA:昆虫成分的复杂混合物)来改善哮喘样过敏性肺炎症。
我们比较了在气管内过敏原致敏和挑战前接受四次 CRA 喂养的小鼠的肺部炎症与在同一时间过程中接受 PBS 喂养的小鼠的肺部炎症。通过全身无约束 plethysmography 和强制振荡的机械通气评估呼吸参数。通过 ELISA 评估支气管肺泡灌洗液(BAL)和肺匀浆(LH)中的细胞因子和趋化因子。还收集和检查 BAL 炎症细胞的光镜。
在过敏原致敏和挑战前进行 CRA 喂养可显著改善呼吸健康。与 PBS 喂养的小鼠相比,CRA 喂养的小鼠通过间接测量增强的停顿(Penh)测量的气道高反应性显著降低(2.3 ± 0.4 对 3.9 ± 0.6;p = 0.03)。当比较 CRA 喂养和 PBS 喂养的动物时,直接测量气道阻力证实了这一趋势(2.97 ± 0.98 对 4.95 ± 1.41)。这种效果不是由于传统炎症细胞趋化因子、Th2 或其他细胞因子和趋化因子的减少所致。耐受小鼠呼吸健康改善的机制是由于支气管肺泡灌洗液中的嗜酸性粒细胞数量显著减少(43300 ± 11445 对 158786 ± 38908;p = 0.007)和肺匀浆中嗜酸性粒细胞特异性过氧化物酶活性降低(0.59 ± 0.13 对 1.19 ± 0.19;p = 0.017)。耐受小鼠肺匀浆中白细胞介素 10 的增加可能是嗜酸性粒细胞减少的结果(6320 ± 354 ng/mL 对 5190 ± 404 ng/mL,p = 0.02)。
我们的结果表明,口服耐受 CRA 可以通过减少肺嗜酸性粒细胞来改善实验小鼠在 CRA 诱导的哮喘样肺炎症模型中的呼吸健康。